Global News
-
30-08-2010Sandoz receives FDA approval for another new indication for Omnitrope® and launches Patient Assistance Program
Sandoz announced today that the US Food and Drug Administration (FDA) has approved its human growth hormone Omnitrope® (somatropin [rDNA origin] for injection) for another new indication, the treatment of Idiopathic Short Stature (ISS).
-
23-07-2010Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®[1]
Holzkirchen, July 23, 2010 – Sandoz today announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®[1], in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA).
-
15-07-2010Novartis quarterly results Q2 2010
Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation.
-
28-06-2010Sandoz opens new state-of-the-art development center in East Hanover, NJ
Princeton, NJ, June 11, 2010 - Sandoz celebrated this week the formal launch of its new product development center located in East Hanover, New Jersey. The new development center will be a key site for Sandoz US development of generic medicines, with an emphasis on "first-to-file" applications with the FDA.
-
03-06-2010Sandoz completes acquisition of Oriel Therapeutics, strengthening potential for global leadership in respiratory
Princeton, New Jersey; June 3, 2010– Sandoz announced today that it has completed its acquisition of Oriel Therapeutics, a privately held US pharmaceuticals company, for an undisclosed sum.
-
26-05-2010NICE issues first biosimilar recommendation, saying Omnitrope® offers same efficacy and safety as other somatropins
Holzkirchen, May 26, 2010 – The UK’s National Institute for Health and Clinical Excellence (NICE) today published final guidance on the relative cost and effectiveness of somatropin products to treat child growth deficiencies1.
-
20-04-2010Novartis quarterly results Q1 2010
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity
-
19-04-2010Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD
Holzkirchen, Germany, April 19, 2010 - Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company, gaining exclusive rights to a portfolio of generic drug candidates and related technologies targeting medicines in the inhalable respiratory drug market. Terms of the deal were not disclosed.
-
08-04-2010Sandoz launches authorized versions of Cozaar® and Hyzaar® tablets
Princeton, NJ, April 7, 2010 —Sandoz Inc. announced today the introduction in the US of losartan potassium and losartan potassium-hydrochlorothiazide (HCTZ) tablets, authorized generic equivalents of Merck's Cozaar® and Hyzaar®.
-
01-04-2010Generic Medicines: Essential contributors to the long-term health of society
IMS's Alan Sheppard looks at the sustainability of the generics sector and assesses its benefits to the provision of healthcare across Europe.
